P1.01-15 ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated With High Rate of Venous Thromboembolism: Analysis of the METROS Trial

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.571
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.01-50 Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Crizotinib in MET Deregulated or ROS1 Rearranged Pretreated Non-Small-Cell Lung Cancer (METROS): A Phase II, Prospective, Multicentre, Two-Arms Trial

Clinical Cancer Research
Cancer ResearchOncology
2019English

P1.01-78 the Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-113 Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-01 ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2015English

Prevalence of ROS1 Fusion in Chinese Patients With Non-Small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

PD‑L1 Expression Is Associated With Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2016English

Overexpression of OCT4 Is Associated With Gefitinib Resistance in Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy